137.35
price up icon0.53%   0.72
after-market After Hours: 137.35
loading
Neurocrine Biosciences Inc stock is traded at $137.35, with a volume of 659.64K. It is up +0.53% in the last 24 hours and down -3.19% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$136.63
Open:
$136.85
24h Volume:
659.64K
Relative Volume:
0.76
Market Cap:
$13.62B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
46.56
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-1.49%
1M Performance:
-3.19%
6M Performance:
+51.15%
1Y Performance:
+18.93%
1-Day Range:
Value
$135.63
$139.56
1-Week Range:
Value
$135.63
$141.14
52-Week Range:
Value
$84.23
$154.61

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
137.35 13.55B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
142.26 62.54B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.72 43.30B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.08 40.08B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.02 22.98B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
440.06 19.90B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-25 Initiated Truist Buy
Jul-10-25 Initiated Goldman Buy
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
10:35 AM

Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com

10:35 AM
pulisher
10:14 AM

How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com

10:14 AM
pulisher
05:54 AM

United States Huntington's Disease Market is expected to reach - openPR.com

05:54 AM
pulisher
05:28 AM

Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionMarket Risk Analysis & Growth Focused Stock Reports - newser.com

05:28 AM
pulisher
Oct 12, 2025

Is Neurocrine Biosciences Inc a good long term investmentChart Pattern Recognition & Ride the Trends That Billionaires Follow - earlytimes.in

Oct 12, 2025
pulisher
Oct 11, 2025

Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment - simplywall.st

Oct 11, 2025
pulisher
Oct 10, 2025

Using data models to predict Neurocrine Biosciences Inc. stock movementOil Prices & Weekly Top Gainers Trade List - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Market reaction to Neurocrine Biosciences Inc.’s recent newsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

UBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Using economic indicators to assess Neurocrine Biosciences Inc. potential2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Neurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

How to forecast Neurocrine Biosciences Inc. trends using time seriesJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Full technical analysis of Neurocrine Biosciences Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can Neurocrine Biosciences Inc. stock maintain growth trajectoryMarket Trend Review & Accurate Trade Setup Notifications - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Neurocrine Bio. stock price target raised to $195 from $188 at UBS - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Why Neurocrine Biosciences Inc. (NB3) stock fits value portfoliosQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Neurocrine Biosciences publishes positive data from movement disorder study - MSN

Oct 09, 2025
pulisher
Oct 08, 2025

RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - Eastern Progress

Oct 08, 2025
pulisher
Oct 07, 2025

Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan

Oct 07, 2025
pulisher
Oct 07, 2025

How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st

Oct 07, 2025
pulisher
Oct 07, 2025

A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance

Oct 07, 2025
pulisher
Oct 07, 2025

Neurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc. - MarketBeat

Oct 07, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Demonstrates 77.8% PGI-C Response at 3 Years | NBIX Stock News - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail

Oct 04, 2025
pulisher
Oct 04, 2025

Pure Financial Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Will breakout in Neurocrine Biosciences Inc. lead to full recoveryRate Cut & Safe Entry Point Identification - newser.com

Oct 03, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Neurocrine Biosciences Inc Stock (NBIX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
GORMAN KEVIN CHARLES
Director
Aug 07 '25
Sale
126.41
106,322
13,440,281
514,596
drug_manufacturers_specialty_generic RDY
$14.36
price up icon 0.14%
$54.73
price up icon 1.45%
$9.86
price up icon 1.23%
$20.04
price up icon 1.42%
$440.06
price up icon 0.01%
Cap:     |  Volume (24h):